Implants incorporating nanotubes and methods for producing the same
A surface-modified implant comprising a plurality of nanotubes and a process for preparing the surface-modified implant. The metal-containing surface of the implant is modified using an electrochemical anodization process to create a plurality of nanotubes formed of an oxide of the metal on at least a surface of the implant.
1 . A surface modified implant having at least a metal-containing surface, comprising a plurality of nanotubes on the surface, where the nanotubes are comprised of an oxide of the metal-containing surface.
2 . The surface modified implant of claim 1 , where the metal-containing surface comprises a metal selected from the group consisting of titanium, titanium alloys, tantalum, tantalum alloys, stainless steel alloys, cobalt-based alloys, cobalt-chromium alloys, cobalt-chromium-molybdenum alloys, niobium alloys, and zirconium alloys.
3 . The surface modified implant of claim 1 , where the nanotubes comprise oxides of a metal or alloy selected from the group consisting of titanium, titanium alloys, tantalum, tantalum alloys, stainless steel alloys, cobalt-based alloys, cobalt-chromium alloys, cobalt-chromium-molybdenum alloys, niobium alloys, and zirconium alloys.
4 . The surface modified implant of claim 1 , where the metal-containing surface comprises commercially pure titanium and the nanotubes comprise titanium oxide.
5 . The surface modified implant of claim 1 , where the metal-containing surface comprises a titanium alloy and the nanotubes comprise titanium oxide.
6 . The surface modified implant of claim 5 , where the titanium alloy is Ti-6Al-4V and the nanotubes comprises titanium oxide, aluminum oxide, vanadium oxide, or mixtures and combinations thereof.
7 . The surface modified implant of claim 1 , where the inner pore diameter of the nanotubes is between about 15 nanometers and about 100 nanometers.
8 . The surface modified implant of claim 1 , where the outer pore diameter of the nanotubes is between about 15 nanometers and about 200 nanometers.
9 . The surface modified implant of claim 1 , where the height of the nanotubes is between about 15 nanometers and about 5000 nanometers.
10 . The surface modified implant of claim 1 , where the nanotubes are formed on the metal-containing surface by an electrochemical anodization process.
11 . The surface modified implant of claim 1 , where the surface modified implant is an implant selected from the group consisting of a bone implant, stent, drug depot, and fusion cage.
12 . A process for modifying a metal-containing surface of an implant to form a plurality of oxide nanotubes on the surface of the implant, comprising:
providing an electrolyte solution;
providing a cathode;
immersing the implant in the electrolyte solution; and
applying a voltage between the implant and the cathode in the electrolyte solution.
13 . The process of claim 12 , where the metal-containing surface of the implant comprises titanium or a titanium alloy.
14 . The process of claim 12 , where the oxide nanotubes comprise titanium oxide or oxides of a titanium alloy.
15 . The process of claim 12 , where the electrolyte solution comprises chromic acid and hydrofluoric acid.
16 . The process of claim 12 , where the voltage between the implant and the cathode is between about 1 V and about 40 V.
17 . The process of claim 12 , where a biological agent or additive is adsorbed onto or incorporated into the modified surface of the implant.
18 . The process of claim 12 , where the implant is an implant selected from the group consisting of a bone implant, stent, drug depot, and fusion cage.
19 . A process for modifying the surface of an implant, comprising:
providing an implant comprising at least a surface containing titanium or titanium alloy;
immersing the implant and a cathode in an acidic electrolyte solution including hydrofluoric acid; and
applying an electrical potential between the implant and the cathode;
wherein a plurality of nanotubes of titanium oxide or oxides of the titanium alloy are formed on the surface of the implant.
20 . The process of claim 19 , where the concentration of hydrofluoric acid in the electrolyte solution is between about 0.5% by weight and about 1.5% by weight.
21 . The process of claim 19 , where the electrolyte solution comprises a solution of chromic acid and hydrofluoric acid.
22 . The process of claim 21 , where the concentration of chrornic acid in the electrolyte solution is about 0.5 moles per liter of water.
23 . The process of claim 19 , where the electrical potential is between about 1 V and about 40 V.
24 . The process of claim 23 , where the electrical potential is about 20 V.
25 . The process of claim 19 , where the implant is cleaned before immersing the implant in the electrolyte solution.
26 . The process of claim 19 , where the implant is annealed after formation of the nanotubes on the surface of the implant.
27 . The process of claim 26 , where the implant is annealed at a temperature less than about 580° C.
28 . The process of claim 27 , where the implant is annealed at a temperature between about 280° C. and about 430° C.
29 . The process of claim 27 , where the implant is annealed at a temperature between about 430° C. and about 580° C.
30 . The process of claim 19 , where a biological agent or additive is adsorbed onto or incorporated into the modified surface of the implant.
31 . The process of claim 30 , where the biological agent or additive is selected from the group consisting of sugars; nucleic acid and amino acid sequences; vitamins; inorganic elements; co-factors for protein synthesis; hormones; endocrine tissue or tissue fragments; synthesizers; enzymes; polymer cell scaffolds; angiogenic agents; antigenic agents; cytoskeletal agents; cartilage fragments; living cells; autogenous tissues; somatotropin; bone digesters; antitumor agents and chemotherapeutics; permeation enhancers; bisphosphonates; pain killers and anti-inflammatories; antibiotics and antiretroviral drugs; and salts.
32 . The process of claim 19 , where the implant is an implant selected from the group consisting of a bone implant, stent, drug depot, and fusion cage.
33 . The surface modified implant of claim 1 , where the implant additionally comprises an implant body to which the metal-containing surface is attached.
34 . The surface modified implant of claim 33 , where the metal-containing surface is a metal layer covering all or a portion of the surface of the implant.
35 . The surface modified implant of claim 34 , where the metal layer is attached to the implant body by cladding the implant body with the metal layer, by depositing the metal layer by sputtering, or by depositing the metal layer by electroplating the metal layer to the implant body.